Riskpilot← Back to searchSign inGet full accessNeuropharma Solutions AB
ABActiveOrg 5593842635Ingrid Mariegatan 16 KMedical specialists activities · NACE 8622Est. 20220 employees
Revenue 2024
SEK 19K
+1914900% vs 2023
EBITDA margin
55.0%
+1395% vs 2023
Equity ratio
85.3%
Financial strength
Net profit 2024
SEK 8K
+2214% vs 2023
| Revenue | SEK 19K | +1914900% |
| EBITDA | SEK 11K | +1395% |
| Net profit | SEK 8K | +2214% |
| Total assets | SEK 38K | -34% |
| Equity | SEK 33K | +32% |
| Employees | 0 | — |
Legal name
Neuropharma Solutions AB
Org number
5593842635
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
9 juni 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Företaget ska bedriva konsultverksamhet inom apotek och sjukvård. Inom apoteksområdet erbjuds tjänster av legitimerad receptarie till både slutenvårds- och öppenvårdsapotek. Inom hälso- och sjukvård erbjuds specialistläkartjänster inom neurologi, där en legitimerad specialistläkare hyrs ut till privata vårdgivare, aktörer med vårdavtal samt statliga specialistenheter i Sverige och Norge.
Address
Ingrid Mariegatan 16 K
Email
florabashota@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 73 | 73 | 0 | 19 |
| Staff expenses | — | −0 | — | — |
| EBITDA | 73 | 73 | −1 | 11 |
| Depreciation & amort. | −0 | −0 | — | — |
| EBIT | 73 | 73 | −1 | 11 |
| Net financials | — | 0 | 0 | −1 |
| Profit before tax | 73 | 73 | −0 | 10 |
| Tax | −15 | 15 | — | −2 |
| Net profit | 58 | 58 | −0 | 8 |
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 98 | 98 | 58 | 38 |
| Equity | 83 | 83 | 25 | 33 |
| Long-term debt | 0 | 0 | — | — |
| Short-term debt | 15 | 15 | 33 | 6 |
| Total debt | 15 | 15 | 33 | 6 |
EBITDA margin
55.0%
This company
15.8%
Market median
+248% vs market
20222024
Equity ratio
85.3%
This company
38.2%
Market median
+123% vs market
20222024
Return on equity
24.4%
This company
18.4%
Market median
+33% vs market
20222024
Net profit margin
41.4%
This company
8.1%
Market median
+411% vs market
20222024
Asset turnover
0.50×
This company
1.12×
Market median
-55% vs market
20222024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-06-09 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-06-01 – 2022-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2026 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Neuropharma Solutions AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Flora Bashota | Board of Directors | 0 companies |
| Pashtrik Nerjovaj | Deputy Board Member | 0 companies |
| Florin Bashota | Deputy Board Member | 0 companies |